Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cj Tech Holdings Pte. Ltd. operates a patent portfolio situated in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action, reflecting a specific stage of prosecution. This singular pending action suggests a narrow window of active engagement with the patent office at this time. For the company, this represents a highly targeted approach to its intellectual property development.
Examination of this portfolio is handled by a distinct examiner across a single art unit. Such a distribution points to a focused technical scope that falls under the jurisdiction of a single administrative group. CRAIGO, WILLIAM A is the busiest examiner associated with these filings. The concentration in a single art unit allows for a consistent application of examination standards.
With 1 busiest examiner pending office action, CRAIGO, WILLIAM A manages the entirety of the active workload. Practitioners should note that the prosecution experience is currently defined by the interpretations of CRAIGO, WILLIAM A. The pending office action provides a focused point of contact for the company's legal strategy in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, WILLIAM A | 1 | 49.2% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006164 | CRYSTALLINE ZIRCONIUM PHOSPHATE FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, AND USE OF THE SAME | CRAIGO, WILLIAM A | 26d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006164 | CRYSTALLINE ZIRCONIUM PHOSPHATE FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, AND USE OF THE SAME | CRAIGO, WILLIAM A | 26d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18006164 | CRYSTALLINE ZIRCONIUM PHOSPHATE FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, AND USE OF THE SAME | CRAIGO, WILLIAM A | 1615 | §102§103 | Final Rejection | 26d overdue | Pending | Jan 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial